Objectives Tinea capitis is a common paediatric infection for which Griseofulvin is the only licensed medication. However azole antifungals are readily available and may be efficacious in this cohort of patients.
Methods We conducted a retrospective study which investigated the efficacy and safety of oral Itraconazole in the management of tinea capitis; 86 children of varying ethnicity who attended our department over a 2 year period were included. All patients had a clinical diagnosis of tinea capitis and were treated with oral Itraconazole at doses ranging from 3 to 5 mgs/kg/day. Fungal scrapings were obtained from 54 patients, of whom 34 had positive cultures. Trichophyton tonsurans was the most common organism.
Results 17 patients failed to attend after the initial visit; of the remaining 69 patients, clinical cures were documented in 43 (62.3%) after 6 weeks or less of Itraconazole, a further 14 (20.3%) resolved after 6–12 weeks of treatment, while 4 (5.8%) did not respond and required introduction of another agent.
Of the 31 patients with confirmed Trichophyton species, clinical cures were recorded in 56% after less than 6 weeks of treatment and a further 20% were cured after 6–12 weeks. Of the 3 patients with confirmed M. canis, 1 patient had a partial response after 6 weeks of oral Itraconazole while 2 patients were unresponsive. Itraconazole was well tolerated in all cases with no recorded side effects.
Conclusions In summary, Itraconazole is a safe and effective option for childhood tinea capitis. Trichophyton species are particularly responsive but Microsporum infections appear much more resistant.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.